India on Monday raised serious concerns over the USFDA's audit inspections of Indian pharma companies and 'disproportionate penalties' in some instances and said it would submit a discussion document on the issues to the US.
DCGI, health ministry initiate dialogues with foreign regulators, try to understand global best practices
Low growth visibility and trouble with regulators have resulted in lack of interest from investors
The US seems to be engaging in a game of brinkmanship where President Trump's visit has been used as 'leverage' to pressure India into agreeing to a trade deal, notes Kashish Parpiani.
Sanjeev Nayyar offers a roster of things to do to see the India of our dreams.
General Mattis has been the most steadfast champion in Trump's cabinet of the US-India defence relationship. If Trump chooses a more pliable successor, the Pentagon's attention could go off India.
All of Ranbaxy's India-based factories are currently banned by the FDA from exporting medicines to the United States, the company's largest market, after the regulator's inspection found violation of its so-called good manufacturing practices.
The Department of Commerce alleged that Huawei was engaged in activities that are contrary to US national security or foreign policy interest.
The FDA has stepped up its efforts to ensure drug safety in recent months.
Economic Survey says Services Sector Negotiations at WTO Crucial.
Ranbaxy Laboratories is recalling 29,790 blister packs of anti-allergy drug in the US, manufactured by its arm Ohms Laboratories, due to defective packaging.
Over 15 years, with seven per cent growth, the Indian economy will be three times bigger.
Mr Prabhu has a big challenge ahead in implementing trade reforms to regain the lost export momentum, says Jayanta Roy.
The United States, the United Kingdom, the European Union and NATO have expressed concern on the new law and warned of retaliatory measures.
'Success will require political skill, not just economic expertise'
Nestle refused to regret the mistake in a public statement.
A spokesman for Gibraltar's government also confirmed that police proceedings against four members of the crew had ended.
One indictment accuses Huawei of trying to steal trade secrets from T-Mobile, and of promising bonuses to employees who collected confidential information on competitors. A second indictment claims the company worked to skirt US sanctions on Iran.
The Indian Pharmaceutical Alliance has approached regulator for a dialogue to understand the concern raised by it
The RBI is considering permitting FII and commercial banks to trade on Indian commodity exchanges.
The shift to gross calorific value-based grading of coal aligned domestic prices with international benchmarks.
The beef ban has sparked considerable debate and confusion
Reduce the government stake in public sector banks to 33 per cent, recommends A K Bhattacharya
The Budget will obviously be crucial. But US President Donald Trump may have even more of an influence than Finance Minister Arun Jaitley when it comes to sentiment, argues Devangshu Datta.
Making nuclear exemptions for India, says Senator Edward Markey, 'only infuriates Pakistan and leads them to further increase their own nuclear capacities.'
The apex court asked the counsel for the Centre to specify the status of rules which were to be formulated in pursuance of its direction to protect cattle smuggling to Nepal and posted the matter for further hearing after summer vacation from May 10 till July 2.
Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.
Maggi noodles was recalled in June because some states had found presence of MSG and excessive lead content in the samples.
Inspections only in domestic authorities' presence, visiting US drug regulator told
South-east Asian countries are emerging as preferable destination for India's pharma companies to expand their business as they share similar patient population and disease profile and moreover, have a conducive environment for their operations like easy market approach without any regulatory uncertainty, the survey of Indian pharma firms highlighted.
Here's the full text of President's Ram Nath Kovind's address to the joint sitting of both houses of Parliament on the first of Budget Session 2022.
'We are only talking about 65,000 H1B visas a year, it is not going to go down drastically.' 'If the number reduces and when you spread that reduction across all the top IT services companies, the impact will be marginal.'
There are just 1,500 drug inspectors responsible for more than 10,000 factories in India
The joint entity will have a market share of nine per cent in India. Analysts tracking the company said one of the key outcomes of the merger would be to create a single brand entity of Sun and the Ranbaxy brand would eventually dissolve.
Clarity on the roadmap necessary to assess its likely impact on near-term fiscal health and investment.
The rap from both the US and UK drug regulators, including the latest one from the latter, has hit the scrip.
During the meeting with Acting Deputy US Trade Representative Wendy Cutler on Wednesday,
Realistically, coal will be the major fuel for electricity generation in India, as in America, for a long time.
Growth in India is expected to remain strong and stable in 2015
On her maiden visit to India, US Food and Drug Administrator Margaret A Hamburg has said recent lapses in quality by a handful of pharma companies has overshadowed the good things done by other Indian companies, who emphasise on quality products and practices.
